Skip to main content

Table 4 Visual evoked potentials in the study groups

From: Clinical utility of complex assessment with evoked potentials in acute lymphoblastic leukemia survivors: comparison of various treatment protocols

 

NY

pBFM

BFM95

Control

P value

Prolonged N70 latency

6 (17.1)

3 (6.4)

6 (12.2)

–

0.375

Prolonged P100 latency

13 (37.1)

10 (21.3)

31 (63.3)

–

0.541

Decreased P100 amplitude

6 (17.1)

1 (2.1)

0 (0.0)

–

0.001

Prolonged N135 latency

22 (62.9)

17 (36.2)

43 (87.8)

–

0.786

N70 latency

71.82

69.35

69.62

70.71

0.355

P100 latency

107.23

103.86

107.32

101.62

0.005*

P100 amplitude

10.17

9.24

12.55

12.31

0.019

N135 latency

152.17

148.18

153.03

138.22

< 0.001**

  1. * NY vs control P = 0.050, BFM95 vs control P = 0.044
  2. ** NY vs control P = 0.001, pBFM vs control P = 0.028. BFM95 vs control P < 0.001
  3. Abbreviations: BFM Berlin-Frankfurt-Münster protocol, NY New York protocol